NCT05049161View on ClinicalTrials.gov

A Long-term Extension of Study GNC-401

PHASE2TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

May 18, 2022

Study Completion Date

May 18, 2022

Conditions
Multiple Sclerosis
Interventions
DRUG

Temelimab 18 mg/kg

temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)

DRUG

Temelimab 36mg/kg

temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)

DRUG

Temelimab 54 mg/kg

temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)

Trial Locations (1)

113 65

Center for Neurology, Academic Specialist Center, Stockholm

Sponsors
All Listed Sponsors
lead

GeNeuro Innovation SAS

INDUSTRY